# Blind claim-grounding calibration

Label whether each complete cited span explicitly supports the entire claim. Use only the shown span. Every material entity, variant, condition, direction, magnitude, population, time and uncertainty qualifier must be supported.

Silence cannot support a scientific negative such as no association, no effect or no reported outcome. Every component of a compound claim must be supported. A caption can support a result it states explicitly. If a result is only encoded in an unavailable figure, label it unsupported and enter `figure_required` as the failure subtype. Judge claim-to-span support only, not whether the claim answers the original query.

Choose one label per pair and explain unsupported decisions. Do not inspect the separate manifest or any automated judge output until all labels are complete.

---

## GCV1-001

**Claim:** The S4 polygenic risk score is associated with a 1.38‑fold increased risk of non‑mucinous ovarian cancer per standard deviation in women of European ancestry (OR=1.38, 95% CI 1.28–1.48).

**Citation:** `PMC8904525`, `abstract`, characters 0:1820

**Complete cited source span:**

> Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28–1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08–1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21–1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29–1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35–1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states the S4 model has an odds ratio (OR) of 1.38 (95% CI: 1.28–1.48) per unit standard deviation in women of European ancestries for non-mucinous EOC (epithelial ovarian cancer).


---

## GCV1-002

**Claim:** General BRCA1 mutations are associated with increased prostate cancer risk, but no data for c.4484+2T>C

**Citation:** `PMC5155186`, `body`, characters 6908:7717

**Complete cited source span:**

> Association of BRCA1/2 mutations with susceptibility to breast and ovarian cancer has been investigated for years. It is estimated that about 60% of women with BRCA1/2 mutations have developed breast cancer[14]. A woman who carries a germline BRCA1/2 mutation could be 5 times more likely to develop breast cancer than one who does not carry any BRCA1/2 mutation[15]. Men who have BRCA1/2 mutations are more likely to have prostate or pancreatic cancers. Men are 3.5 times and 8.6 times more likely to develop prostate cancer for BRCA1 and BRCA2 mutation carriers by age 65, respectively[16]. Similar to prostate cancer, BRCA1/2 poses a risk of pancreatic cancer development. Overall, BRCA1 mutation increases the risk by 0- to 4.11-fold, while the BRCA2 mutation increases the risk by 2.13- to 21.7-fold[17].

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** While the span supports that general BRCA1 mutations are associated with increased prostate cancer risk (3.5 times more likely), it completely lacks any mention of the "c.4484+2T>C" variant or a lack of data for it. Silence cannot support a scientific negative.


---

## GCV1-003

**Claim:** Low levels of retained ATM activity may still allow tumor development later in life (e.g., breast cancer).

**Citation:** `PMC2386480`, `body`, characters 0:2149

**Complete cited source span:**

> The incidence of breast cancer in Chile is still increasing but the mortality rate in the last decade has remained constant. Early detection contributes to mortality reduction and genetic testing may identify high-risk individuals. Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have been identified as high penetrance alleles. However, these alleles explain only a small fraction of familial breast cancers [1,2]. We have previously screened for germ line mutations in BRCA1/2, 64 Chilean families with several cases of breast and/or ovarian cancer [3]. Only 15.6% of these presented mutations in one of these two genes. The most widely accepted model proposes that familial breast cancer susceptibility is a consequence of a small number of mutations in BRCA1/2 and a much larger variability in ethnic-specific genes of moderate and/or low penetrance [4]. The Ataxia-Telangiectasia Mutated gene (ATM) has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene. The ATM kinase has an essential role in maintaining genomic integrity. It is a key activator of the cellular responses to DNA double-strand breaks [5]. Individuals heterozygous for ATM mutations have been reported to have an increased risk for female breast cancer. A number of studies have searched for germ line ATM mutations in breast cancer cases and/or compared the frequency of common ATM variants among breast cancer cases to population controls, but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory [6,7]. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles [6,8]. There was no evidence that other classes of ATM variants confer a risk of breast cancer [8]. A common ATM variant IVS38-8T>C in cis with the 5557G>A ATM variant, has been suggested to be associated with bilateral breast cancer [9]. The 5557G>A variant has previously been reported in the homozygous state to associate with enhanced clinical radiosensitivity in breast cancer patients [10-12].

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses ATM mutations as breast cancer susceptibility alleles but does not explicitly mention "low levels of retained ATM activity" or tumor development "later in life".


---

## GCV1-004

**Claim:** Polygenic risk scores stratify ovarian cancer risk in BRCA1 carriers, with higher PRS percentiles showing higher cumulative risk

**Citation:** `PMC8904525`, `abstract`, characters 0:1820

**Complete cited source span:**

> Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28–1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08–1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21–1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29–1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35–1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span provides a hazard ratio for BRCA1 carriers using the S4 PRS but does not explicitly discuss stratifying risk by PRS percentiles or showing higher cumulative risk for higher percentiles.


---

## GCV1-005

**Claim:** BRCA1/BRCA2 loss‑of‑function mutations are linked to increased pancreatic cancer risk

**Citation:** `PMC7788890`, `abstract`, characters 0:632

**Complete cited source span:**

> In addition to ovarian and breast cancers, loss-of-function mutations in BRCA1 and BRCA2 genes are also linked to an increased risk of pancreatic cancer, with ~ 4 to 7% of pancreatic cancer patients harboring germline BRCA mutations. Most BRCA alterations in pancreatic cancer are frame-shifting indels, stop-gain, and splice-site mutations, but single nucleotide substitutions are rare. Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline BRCA mutations and metastatic pancreatic cancer.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that loss-of-function mutations in BRCA1 and BRCA2 genes are linked to an increased risk of pancreatic cancer.


---

## GCV1-006

**Claim:** Knockdown of SREBP pathway genes decreases mutant TP53 mRNA and protein levels in hepatocellular carcinoma cells

**Citation:** `PMC11894594`, `abstract`, characters 0:1970

**Complete cited source span:**

> Hepatocellular carcinoma (HCC) is a severe disease associated with a poor prognosis. The role of aberrant lipid metabolism in the development and progression of HCC necessitates detailed characterization. Sterol regulatory element-binding proteins (SREBPs), pivotal transcription factors governing lipogenesis, are central to this process. The present study aimed to assess the regulation of HCC by the SREBP signaling pathway, examining the expression levels of genes in this pathway, the clinical implications and its prognostic value using the Kaplan-Meier method. Pearson's correlation coefficient was used to identify the co-expression of SREBP pathway genes in HCC. Genomic analysis examined the frequency of TP53 mutations in groups with and without SREBP pathway alterations. In addition, small interfering RNAs targeting genes of the SREBP pathway were transfected into Huh-7 and HCC-LM3 cell lines. Subsequently, Cell Counting Kit-8 and Transwell assays were carried out to evaluate the viability and invasion of these cells. Reverse transcription-quantitative PCR and western blotting were performed to investigate the expression of TP53 in response to silencing of SREBP pathway genes. Dysregulation of SREBP pathway genes was detected in HCC tissues compared with in normal liver tissues, and predicted a poor prognosis. Silencing these genes reduced the viability and invasion of HCC cells. Furthermore, abnormal SREBP pathway gene expression was associated with poor survival rates, vascular invasion, advanced tumor stage and an increased incidence of TP53 mutations. By contrast, knockdown of SREBP pathway genes decreased mutant TP53 expression at both the mRNA and protein levels in HCC cells. The findings of the present study suggested that SREBP pathway genes could serve as promising prognostic biomarkers for HCC. The combined analysis of individual gene expression levels offers offer novel insights into the pathogenesis and progression of HCC.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that knockdown of SREBP pathway genes decreased mutant TP53 expression at both mRNA and protein levels in HCC cells.


---

## GCV1-007

**Claim:** The BAP1 F170I mutant preferentially localizes to the cytoplasm rather than the nucleus.

**Citation:** `PMC4582980`, `abstract`, characters 0:1714

**Complete cited source span:**

> BRCA1-associated protein 1 (BAP1) is a deubiquitinating enzyme that is involved in the regulation of cell growth. Recently, many somatic and germline mutations of BAP1 have been reported in a broad spectrum of tumors. In this study, we identified a novel somatic non-synonymous BAP1 mutation, a phenylalanine-to-isoleucine substitution at codon 170 (F170I), in 1 of 49 patients with esophageal squamous cell carcinoma (ESCC). Multiplex ligation-dependent probe amplification (MLPA) of BAP1 gene in this ESCC tumor disclosed monoallelic deletion (LOH), suggesting BAP1 alterations on both alleles in this tumor. The deubiquitinase activity and the auto-deubiquitinase activity of F170I-mutant BAP1 were markedly suppressed compared with wild-type BAP1. In addition, wild-type BAP1 mostly localizes to the nucleus, whereas the F170I mutant preferentially localized in the cytoplasm. Microarray analysis revealed that expression of the F170I mutant drastically altered gene expression profiles compared with expressed wild-type BAP1. Gene-ontology analyses indicated that the F170I mutation altered the expression of genes involved in oncogenic pathways. We found that one candidate, TCEAL7, previously reported as a putative tumor suppressor gene, was significantly induced by wild-type BAP1 as compared to F170I mutant BAP1. Furthermore, we found that the level of BAP1 expression in the nucleus was reduced in 44% of ESCC examined by immunohistochemistry (IHC). Because the nuclear localization of BAP1 is important for its tumor suppressor function, BAP1 may be functionally inactivated in a substantial portion of ESCC. Taken together, BAP1 is likely to function as a tumor suppressor in at least a part of ESCC.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that wild-type BAP1 mostly localizes to the nucleus, whereas the F170I mutant preferentially localized in the cytoplasm.


---

## GCV1-008

**Claim:** BRCA2 mutations confer a higher pancreatic cancer risk than BRCA1 mutations.

**Citation:** `PMC11694537`, `body`, characters 19579:20043

**Complete cited source span:**

> In conclusion, we report on the cumulative pancreatic cancer incidence and age‐specific risks among a large cohort of women carrying a BRCA1/2 mutation. Pancreatic cancer risk is higher in BRCA2 mutation carriers than in BRCA1 mutation carriers, and BRCA1/2 mutation carriers rarely develop pancreatic cancer before age 50 years. This information will be important for counseling BRCA1/2 mutation carriers and for developing appropriate risk management strategies.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that pancreatic cancer risk is higher in BRCA2 mutation carriers than in BRCA1 mutation carriers.


---

## GCV1-009

**Claim:** Polygenic risk scores stratify ovarian cancer risk in BRCA1 carriers, with higher PRS percentiles showing higher cumulative risk

**Citation:** `PMC8904525`, `body`, characters 34790:34990

**Complete cited source span:**

> FigureS1: Cumulative risk of ovarian cancer risk in BRCA1 carriers by polygenic risk score percentiles. The lasso (A) and elastic net (B) penalized regression models were applied to individual level g

**Your label:** `unsupported`

**Failure subtype, if applicable:** `figure_required`

**Your rationale:** The text only provides a caption for a figure showing cumulative risk by PRS percentiles. The actual result (higher percentiles showing higher cumulative risk) is encoded in the unavailable figure and not explicitly stated in the text span.


---

## GCV1-010

**Claim:** Approximately 7% of pancreatic acinar cell carcinomas have germline BRCA1 or BRCA2 mutations

**Citation:** `PMC6606020`, `abstract`, characters 259:910

**Complete cited source span:**

> Molecular analysis revealed a germline BRCA2 (and CHEK2) mutation in a patient with a rare pancreatic ACC with extensive intraductal growth. Somatic loss of the wild-type BRCA2 allele in the tumor indicated the causal relationship of ACC with the germline defect. A thorough literature review identified another nine ACCs associated with germline BRCA2 mutation and two ACCs associated with germline BRCA1 mutation, resulting in a prevalence of BRCA1/2 germline mutations in almost 7% of ACCs. Moreover, somatic BRCA1/2 alterations are reported in 16% of sporadic ACCs. Overall, about one fifth (22%) of all pancreatic ACCs exhibit BRCA1/2 deficiency.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states there is a prevalence of BRCA1/2 germline mutations in almost 7% of ACCs (pancreatic acinar cell carcinomas).


---

## GCV1-011

**Claim:** The risk is especially high in women ≤30 years (OR 10.09)

**Citation:** `PMC5408990`, `abstract`, characters 1057:1762

**Complete cited source span:**

> Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2×10−53). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2×10−20). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses absolute risks across PRS deciles for BRCA1 and BRCA2 carriers but does not contain any information about age groups, women ≤30 years, or an odds ratio of 10.09.


---

## GCV1-012

**Claim:** General BRCA1 mutations are associated with increased prostate cancer risk, but no data for c.4484+2T>C

**Citation:** `PMC2386480`, `body`, characters 0:2149

**Complete cited source span:**

> The incidence of breast cancer in Chile is still increasing but the mortality rate in the last decade has remained constant. Early detection contributes to mortality reduction and genetic testing may identify high-risk individuals. Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have been identified as high penetrance alleles. However, these alleles explain only a small fraction of familial breast cancers [1,2]. We have previously screened for germ line mutations in BRCA1/2, 64 Chilean families with several cases of breast and/or ovarian cancer [3]. Only 15.6% of these presented mutations in one of these two genes. The most widely accepted model proposes that familial breast cancer susceptibility is a consequence of a small number of mutations in BRCA1/2 and a much larger variability in ethnic-specific genes of moderate and/or low penetrance [4]. The Ataxia-Telangiectasia Mutated gene (ATM) has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene. The ATM kinase has an essential role in maintaining genomic integrity. It is a key activator of the cellular responses to DNA double-strand breaks [5]. Individuals heterozygous for ATM mutations have been reported to have an increased risk for female breast cancer. A number of studies have searched for germ line ATM mutations in breast cancer cases and/or compared the frequency of common ATM variants among breast cancer cases to population controls, but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory [6,7]. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles [6,8]. There was no evidence that other classes of ATM variants confer a risk of breast cancer [8]. A common ATM variant IVS38-8T>C in cis with the 5557G>A ATM variant, has been suggested to be associated with bilateral breast cancer [9]. The 5557G>A variant has previously been reported in the homozygous state to associate with enhanced clinical radiosensitivity in breast cancer patients [10-12].

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses BRCA1/2 and ATM mutations in the context of breast cancer susceptibility in a Chilean population. It contains no information regarding prostate cancer risk or the c.4484+2T>C variant.


---

## GCV1-013

**Claim:** TP53 mutations were independent predictors of worse survival in chondrosarcoma

**Citation:** `PMC8847983`, `abstract`, characters 0:1948

**Complete cited source span:**

> Small cell carcinoma (SCC) of the uterine cervix is a rare and aggressive form of neuroendocrine carcinoma, which resembles small cell lung cancer (SCLC) in its histology and poor survival rate. Here, we sought to define the genetic underpinning of SCCs of the uterine cervix and compare their mutational profiles with those of human papillomavirus (HPV)‐positive head and neck squamous cell carcinomas, HPV‐positive cervical carcinomas, and SCLCs using publicly available data. Using a combination of whole‐exome and targeted massively parallel sequencing, we found that the nine uterine cervix SCCs, which were HPV18‐positive (n = 8) or HPV16‐positive (n = 1), harbored a low mutation burden, few copy number alterations, and other than TP53 in two cases no recurrently mutated genes. The majority of mutations were likely passenger missense mutations, and only few affected previously described cancer‐related genes. Using RNA‐sequencing, we identified putative viral integration sites on 18q12.3 and on 8p22 in two SCCs of the uterine cervix. The overall nonsilent mutation rate of uterine cervix SCCs was significantly lower than that of SCLCs, HPV‐driven cervical adeno‐ and squamous cell carcinomas, or HPV‐positive head and neck squamous cell carcinomas. Unlike SCLCs, which are reported to harbor almost universal TP53 and RB1 mutations and a dominant tobacco smoke‐related signature 4, uterine cervix SCCs rarely harbored mutations affecting these genes (2/9, 22% TP53; 0% RB1) and displayed a dominant aging (67%) or APOBEC mutational signature (17%), akin to HPV‐driven cancers, including cervical adeno‐ and squamous cell carcinomas and head and neck squamous cell carcinomas. Taken together, in contrast to SCLCs, which are characterized by highly recurrent TP53 and RB1 alterations, uterine cervix SCCs were positive for HPV leading to inactivation of the suppressors p53 and RB, suggesting that these SCCs are convergent phenotypes.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span entirely focuses on small cell carcinoma of the uterine cervix and small cell lung cancer. It contains no mention of chondrosarcoma.


---

## GCV1-014

**Claim:** TOP1 expression is significantly increased in tumors from BRCA1 mutation carriers compared with sporadic (non‑hereditary) breast cancers (p = 0.002; adjusted odds ratio = 3.75, 95% CI 1.85‑7.71).

**Citation:** `PMC5325383`, `abstract`, characters 0:1797

**Complete cited source span:**

> Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1- and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval [95% CI], 1.85 - 7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% CI, 1.08 - 5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly confirms that TOP1 expression is significantly increased in BRCA1-related breast carcinomas relative to sporadic cases (p=0.002) and provides the exact adjusted odds ratio (3.75) and 95% CI (1.85-7.71).


---

## GCV1-015

**Claim:** EGFR mutations are reported in up to 50% of lung adenocarcinoma patients from Peru.

**Citation:** `PMC10192162`, `body`, characters 830:1859

**Complete cited source span:**

> Alterations in the epidermal growth factor receptor (EGFR) gene are among the most common oncogenic driver mutations in the pathogenesis of non-small cell lung cancer (NSCLC). Specific mutations in the EGFR gene are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKI), which offer the best possible results for treatment response in patients with an NSCLC diagnosis and EGFR mutations (EGFRm) [1, 2]. EGFRm presence has been reported in 10–50% of NSCLC cases, almost all in lung adenocarcinomas (LUADs). In addition, significant ethnic variations for EGFRm prevalence have been described, such as 8–15% in LUADs diagnosed in Caucasian patients versus 30–50% in East Asian populations [3, 4]. Among Hispanic populations in Latin America, the frequency of EGFRm in LUADs ranges from 14% in Argentina to 24–35% in Colombia and as high as 50% among Peruvian populations [5–7]. Evaluation of ancestry–mutation association showed that Native American ancestry is positively correlated with EGFRm [8, 9].

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that the frequency of EGFR mutations in lung adenocarcinomas is as high as 50% among Peruvian populations.


---

## GCV1-016

**Claim:** BRCA1/BRCA2 loss‑of‑function mutations are linked to increased pancreatic cancer risk

**Citation:** `PMC6606020`, `abstract`, characters 259:910

**Complete cited source span:**

> Molecular analysis revealed a germline BRCA2 (and CHEK2) mutation in a patient with a rare pancreatic ACC with extensive intraductal growth. Somatic loss of the wild-type BRCA2 allele in the tumor indicated the causal relationship of ACC with the germline defect. A thorough literature review identified another nine ACCs associated with germline BRCA2 mutation and two ACCs associated with germline BRCA1 mutation, resulting in a prevalence of BRCA1/2 germline mutations in almost 7% of ACCs. Moreover, somatic BRCA1/2 alterations are reported in 16% of sporadic ACCs. Overall, about one fifth (22%) of all pancreatic ACCs exhibit BRCA1/2 deficiency.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** While the span notes a prevalence of BRCA1/2 mutations in pancreatic ACCs, it does not explicitly state that these are "loss-of-function" mutations, nor does it explicitly state they are "linked to an increased risk" of pancreatic cancer generally, only reporting their prevalence in a specific tumor subtype.


---

## GCV1-017

**Claim:** The role of ATM heterozygosity in breast cancer risk is uncertain and evidence is mixed

**Citation:** `PMC3170966`, `abstract`, characters 617:1157

**Complete cited source span:**

> In childhood, total absence of ATM kinase activity was associated, almost exclusively, with development of lymphoid tumours. There was an overwhelming preponderance of tumours in patients <16 years without kinase activity compared with those with some residual activity, consistent with a substantial protective effect of residual ATM kinase activity against tumour development in childhood. In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part of the A-T phenotype.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses total absence of ATM kinase activity and breast cancer in A-T patients, but it does not discuss ATM heterozygosity, nor does it state that its role in breast cancer risk is uncertain or that evidence is mixed.


---

## GCV1-018

**Claim:** Per‑standard‑deviation hazard ratios link PRS to increased ovarian cancer risk in BRCA1/BRCA2 carriers

**Citation:** `PMC7788890`, `abstract`, characters 0:632

**Complete cited source span:**

> In addition to ovarian and breast cancers, loss-of-function mutations in BRCA1 and BRCA2 genes are also linked to an increased risk of pancreatic cancer, with ~ 4 to 7% of pancreatic cancer patients harboring germline BRCA mutations. Most BRCA alterations in pancreatic cancer are frame-shifting indels, stop-gain, and splice-site mutations, but single nucleotide substitutions are rare. Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline BRCA mutations and metastatic pancreatic cancer.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span is entirely about pancreatic cancer risk and PARP inhibitors in BRCA1/2 carriers. It contains no information regarding polygenic risk scores (PRS), hazard ratios, or ovarian cancer risk.


---

## GCV1-019

**Claim:** Overexpression of the ABCB1 gene (encoding P‑glycoprotein) is associated with chemoresistance in cancer cells.

**Citation:** `PMC7904762`, `body`, characters 0:520

**Complete cited source span:**

> During the acquisition of chemoresistance, many cancer cells upregulate the expression of transporters mediating drug efflux1,2. Research has therefore focussed on strategies to oppose efflux transporter function3,4. Of these transporters, P-glycoprotein (P-gp, MDR1, gene: ABCB1) has received most attention, and overexpression, stabilisation as well as polymorphisms in the ABCB1 gene are associated with chemoresistance4–6. P-gp is involved in efflux of a range of cellular toxins, and also chemotherapeutic drugs7,8.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that P-glycoprotein is encoded by the ABCB1 gene and that its overexpression is associated with chemoresistance.


---

## GCV1-020

**Claim:** BRCA2 mutations confer a higher pancreatic cancer risk than BRCA1 mutations.

**Citation:** `PMC5155186`, `body`, characters 6908:7717

**Complete cited source span:**

> Association of BRCA1/2 mutations with susceptibility to breast and ovarian cancer has been investigated for years. It is estimated that about 60% of women with BRCA1/2 mutations have developed breast cancer[14]. A woman who carries a germline BRCA1/2 mutation could be 5 times more likely to develop breast cancer than one who does not carry any BRCA1/2 mutation[15]. Men who have BRCA1/2 mutations are more likely to have prostate or pancreatic cancers. Men are 3.5 times and 8.6 times more likely to develop prostate cancer for BRCA1 and BRCA2 mutation carriers by age 65, respectively[16]. Similar to prostate cancer, BRCA1/2 poses a risk of pancreatic cancer development. Overall, BRCA1 mutation increases the risk by 0- to 4.11-fold, while the BRCA2 mutation increases the risk by 2.13- to 21.7-fold[17].

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly supports that BRCA2 mutations confer a higher pancreatic cancer risk (2.13- to 21.7-fold) compared to BRCA1 mutations (0- to 4.11-fold).


---

## GCV1-021

**Claim:** ~4–7% of pancreatic cancer patients harbor germline BRCA mutations

**Citation:** `PMC7788890`, `abstract`, characters 0:632

**Complete cited source span:**

> In addition to ovarian and breast cancers, loss-of-function mutations in BRCA1 and BRCA2 genes are also linked to an increased risk of pancreatic cancer, with ~ 4 to 7% of pancreatic cancer patients harboring germline BRCA mutations. Most BRCA alterations in pancreatic cancer are frame-shifting indels, stop-gain, and splice-site mutations, but single nucleotide substitutions are rare. Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline BRCA mutations and metastatic pancreatic cancer.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that ~4 to 7% of pancreatic cancer patients harbor germline BRCA mutations.


---

## GCV1-022

**Claim:** The variant shows a significant association with breast cancer (OR = 8.5, 95% CI 1.04‑62.46, P = .018)

**Citation:** `PMC10092731`, `abstract`, characters 1:1307

**Complete cited source span:**

> ATM is generally described as a moderate‐risk breast cancer susceptibility gene. However, some of ATM variants might encounter higher risk. ATM c.7570G>C, p.Ala2524Pro, (rs769142993) is a pathogenic Finnish founder variant causative for recessively inherited ataxia‐telangiectasia. At cellular level, it has been reported to have a dominant‐negative effect. ATM c.7570G>C has recurrently been described in Finnish breast cancer families and unselected case cohorts collected from different parts of the country, but the rarity of the allele (MAF 0.0002772 in Finns) and lack of confirming segregation analyses have prevented any conclusive risk estimates. Here, we describe seven families from genetic counseling units with ATM c.7570G>C variant showing co‐segregation with breast cancer. Further analysis of the unselected breast cancer cohort from Northern Finland (n = 1822), a geographical region previously indicated to have enrichment of the variant, demonstrated that c.7570G>C significantly associates with breast cancer, and the risk is estimated as high (odds ratio [OR] = 8.5, 95% confidence interval [CI] = 1.04‐62.46, P = .018). Altogether, these results place ATM c.7570G>C variant among the high‐risk alleles for breast cancer, which should be taken into consideration in genetic counseling.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly provides the exact statistics (OR = 8.5, 95% CI = 1.04-62.46, P = .018) showing the variant's significant association with breast cancer.


---

## GCV1-023

**Claim:** CHEK2 1100delC is associated with worse survival measures beyond 6 years

**Citation:** `PMC13033615`, `abstract`, characters 732:1537

**Complete cited source span:**

> A total of 109 patients (53 females, 56 males; median age, 57 (16–89) years) were included. Tumor grades were G1/ACT (39%), G2 (41%), and G3/dedifferentiated (10%). Median follow‐up was 3.8 years with mortality of 17%. IDH mutations were detected in 59% (IDH1: 64%, IDH2: 36%), with dedifferentiated CS showing highest IDH mutation rate (91%), particularly IDH2. IDH2‐mutations were associated with significantly worse DSS compared to IDH–wild‐type or IDH1‐mutated tumors, independent of tumor grade. Specifically, IDH1‐R132C mutation correlated with significantly improved DSS compared to R132G, and IDH2‐R172S variant showed longest DSS and MFS, whereas IDH2‐R172T was linked to significant poor outcomes. In multivariable analysis, IDH2 and TP53 mutations were independent predictors of worse survival.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses IDH and TP53 mutations in chondrosarcoma. It does not mention the CHEK2 1100delC variant or survival measures beyond 6 years.


---

## GCV1-024

**Claim:** The role of ATM heterozygosity in breast cancer risk is uncertain and evidence is mixed

**Citation:** `PMC137944`, `abstract`, characters 0:1098

**Complete cited source span:**

> The role of ataxia-telangiectasia mutated (ATM) heterozygosity in cancer is uncertain. In vitro studies of cells from ATM heterozygotes provide strong evidence of radiation sensitivity. Some, but not all, clinical studies suggest an increased risk of breast cancer among ATM gene carriers, and this risk may be greater among those exposed to radiation. This possible excess risk of breast cancer associated with ATM heterozygosity constitutes the basis for several genetic epidemiological studies designed to clarify the role that the ATM gene plays in the etiology of breast and other cancers. The primary focus of this international, multidisciplinary, National Cancer Institute-sponsored workshop was to discuss ongoing and planned epidemiologic studies aimed at understanding the complexities of the ATM gene and its role in carcinogenesis. The invited participants were from diverse disciplines including molecular and clinical genetics, radiation biology and physics, epidemiology, biostatistics, pathology, and medicine. In the present meeting report, the aims of each project are described.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that the role of ATM heterozygosity in cancer is uncertain and that clinical evidence is mixed ("Some, but not all, clinical studies suggest...").


---

## GCV1-025

**Claim:** Functional analyses of EAC-derived mutations in ELMO1 reveal increased cellular invasion.

**Citation:** `PMC3678719`, `abstract`, characters 0:992

**Complete cited source span:**

> The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a five-year survival rate of 15%, identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole exome sequencing of 149 EAC tumors/normal pairs, 15 of which have also been subjected to whole genome sequencing. We identify a mutational signature defined by a high prevalence of A to C transversions at AA dinucleotides. Statistical analysis of exome data identified significantly mutated 26 genes. Of these genes, four (TP53, CDKN2A, SMAD4, and PIK3CA) have been previously implicated in EAC. The novel significantly mutated genes include chromatin modifying factors and candidate contributors: SPG20, TLR4, ELMO1, and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 reveal increased cellular invasion. Therefore, we suggest a new hypothesis about the potential activation of the RAC1 pathway to be a contributor to EAC tumorigenesis.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span matches the claim verbatim, explicitly stating that functional analyses of EAC-derived mutations in ELMO1 reveal increased cellular invasion.


---

## GCV1-026

**Claim:** PALB2 germline mutations markedly increase risk for women ≤30 years old

**Citation:** `PMC11694537`, `body`, characters 19579:20043

**Complete cited source span:**

> In conclusion, we report on the cumulative pancreatic cancer incidence and age‐specific risks among a large cohort of women carrying a BRCA1/2 mutation. Pancreatic cancer risk is higher in BRCA2 mutation carriers than in BRCA1 mutation carriers, and BRCA1/2 mutation carriers rarely develop pancreatic cancer before age 50 years. This information will be important for counseling BRCA1/2 mutation carriers and for developing appropriate risk management strategies.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses pancreatic cancer risk for BRCA1/2 mutation carriers. It contains no mention of PALB2 germline mutations or breast cancer risk for women ≤30 years old.


---

## GCV1-027

**Claim:** Higher PRS corresponds to higher absolute risk (6% vs 19% by age 80 for BRCA2 carriers across deciles)

**Citation:** `PMC5408990`, `abstract`, characters 1057:1762

**Complete cited source span:**

> Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2×10−53). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2×10−20). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly confirms that higher PRS deciles correspond to higher absolute risk, specifically citing the 6% (10th percentile) vs 19% (90th percentile) risk by age 80 for BRCA2 carriers.


---

## GCV1-028

**Claim:** PALB2 germline mutations increase breast cancer risk (OR 5.23)

**Citation:** `PMC7384117`, `abstract`, characters 600:1458

**Complete cited source span:**

> A total of 16,501 BRCA1/2‐negative patients with breast cancer were analyzed. Deleterious PALB2 mutation carriers accounted for 0.97% (n = 160) in the breast cancer cohort and for 0.19% (n = 11) in the healthy control cohort. Forty‐one novel PALB2 germline mutations were identified. A high frequency of PALB2 c.751C>T was detected, and it accounted for 10.63% of the PALB2 germline mutations detected (17 of 160). PALB2 mutations were significantly associated with increased breast cancer risk (odds ratio [OR], 5.23; 95% confidence interval [CI], 2.84‐9.65; P < .0001), especially among women 30 years old or younger (OR, 10.09; 95% CI, 3.95‐25.79; P < .0001). Clinical characteristics, including a family history, bigger tumor size, triple‐negative breast cancer, positive lymph nodes, and bilateral breast cancer, were closely related to PALB2 mutations.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that PALB2 mutations are significantly associated with increased breast cancer risk and provides the specific odds ratio of 5.23.


---

## GCV1-029

**Claim:** The variant shows a significant association with breast cancer (OR = 8.5, 95% CI 1.04‑62.46, P = .018)

**Citation:** `PMC7487731`, `abstract`, characters 546:1161

**Complete cited source span:**

> Overall, five BRCA germline mutations were identified (15.1%). The frequency of mutations among patients with family history of breast cancer was 16.7%. Three mutations were found in BRCA1 (9%) and two within the BRCA2 gene (6%). These are three frameshift mutations (c.798_799del, c.2125_2126insA, c.5116_5119delAATA), one missense (c.116G > A) and one nonsense mutation (c.289G > T). The mutation c.5116_5119delAATA has a founder effect in North Africa. Moreover, one variant of unknown significance was identified in BRCA2 (c.4090A > G). Most BRCA mutations carriers (80%) had no family history of breast cancer.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses BRCA1 and BRCA2 mutations and their frequencies, but does not provide any odds ratios, confidence intervals, or P-values matching the claim.


---

## GCV1-030

**Claim:** Low levels of retained ATM activity may still allow tumor development later in life (e.g., breast cancer).

**Citation:** `PMC3170966`, `body`, characters 22355:22938

**Complete cited source span:**

> Two unrelated breast cancer A-T patients were compound heterozygous for the p.Val2716Ala protein, which retains some ATM kinase activity, although greatly reduced compared with normal (Verhagen et al, 2009). Interestingly, development of breast cancer, in A-T patients, may occur either in the total absence of ATM kinase activity (Supplementary Tables S1–S3) or in the presence of a low level of retained ATM activity (Supplementary Table S4), and it is the longer survival of A-T patients with some residual ATM kinase that allows this predisposition for breast cancer to manifest.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that breast cancer can develop in A-T patients with a low level of retained ATM activity because this residual activity allows for longer survival, enabling the predisposition to manifest later.


---

## GCV1-031

**Claim:** OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers

**Citation:** `PMC5408990`, `abstract`, characters 1057:1762

**Complete cited source span:**

> Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2×10−53). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2×10−20). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly and verbatim states that the OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers.


---

## GCV1-032

**Claim:** PALB2 germline mutations increase breast cancer risk (OR 5.23)

**Citation:** `PMC7786920`, `abstract`, characters 0:351

**Complete cited source span:**

> Ataxia telangiectasia-mutated (ATM) gene contributes to repair damaged DNA and to regulate cell cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants and the risk of breast cancer.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span solely discusses ATM variants and their association with breast cancer risk. It does not mention PALB2 or provide an odds ratio of 5.23.


---

## GCV1-033

**Claim:** CHEK2 1100delC is associated with worse survival measures beyond 6 years

**Citation:** `PMC4150261`, `abstract`, characters 1283:1539

**Complete cited source span:**

> The CHEK2 1100delC-associated breast cancer is associated with a higher contralateral breast cancer rate as well as worse survival measures beyond 6 years after diagnosis. No differential sensitivity to adjuvant chemotherapy was observed in CHEK2 patients.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that CHEK2 1100delC-associated breast cancer is associated with worse survival measures beyond 6 years after diagnosis.


---

## GCV1-034

**Claim:** One study found similar survival outcomes, but meta‑analysis indicated worse breast‑cancer specific survival

**Citation:** `PMC7384117`, `abstract`, characters 1459:1774

**Complete cited source span:**

> This study revealed a comprehensive spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer in China. PALB2 germline mutations confer a moderately increased risk for breast cancer but profoundly increase breast cancer risk for those 30 years old or younger in the Chinese population.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses PALB2 germline mutations and breast cancer risk in China. It does not mention meta-analyses, survival outcomes, or breast-cancer specific survival.


---

## GCV1-035

**Claim:** Residual ATM kinase activity provides a protective effect against tumour development

**Citation:** `PMC3170966`, `abstract`, characters 617:1157

**Complete cited source span:**

> In childhood, total absence of ATM kinase activity was associated, almost exclusively, with development of lymphoid tumours. There was an overwhelming preponderance of tumours in patients <16 years without kinase activity compared with those with some residual activity, consistent with a substantial protective effect of residual ATM kinase activity against tumour development in childhood. In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part of the A-T phenotype.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states there is a "substantial protective effect of residual ATM kinase activity against tumour development".


---

## GCV1-036

**Claim:** Absence of ATM kinase activity is linked to a markedly higher risk of lymphoid tumours in childhood

**Citation:** `PMC3170966`, `abstract`, characters 617:1157

**Complete cited source span:**

> In childhood, total absence of ATM kinase activity was associated, almost exclusively, with development of lymphoid tumours. There was an overwhelming preponderance of tumours in patients <16 years without kinase activity compared with those with some residual activity, consistent with a substantial protective effect of residual ATM kinase activity against tumour development in childhood. In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part of the A-T phenotype.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that total absence of ATM kinase activity in childhood is associated with the development of lymphoid tumours, and notes an "overwhelming preponderance" of these tumours in patients without kinase activity.


---

## GCV1-037

**Claim:** OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers

**Citation:** `PMC7384117`, `abstract`, characters 600:1458

**Complete cited source span:**

> A total of 16,501 BRCA1/2‐negative patients with breast cancer were analyzed. Deleterious PALB2 mutation carriers accounted for 0.97% (n = 160) in the breast cancer cohort and for 0.19% (n = 11) in the healthy control cohort. Forty‐one novel PALB2 germline mutations were identified. A high frequency of PALB2 c.751C>T was detected, and it accounted for 10.63% of the PALB2 germline mutations detected (17 of 160). PALB2 mutations were significantly associated with increased breast cancer risk (odds ratio [OR], 5.23; 95% confidence interval [CI], 2.84‐9.65; P < .0001), especially among women 30 years old or younger (OR, 10.09; 95% CI, 3.95‐25.79; P < .0001). Clinical characteristics, including a family history, bigger tumor size, triple‐negative breast cancer, positive lymph nodes, and bilateral breast cancer, were closely related to PALB2 mutations.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses PALB2 mutations and breast cancer risk. It contains no information regarding OC PRS (ovarian cancer polygenic risk scores) or BRCA1/BRCA2 carriers.


---

## GCV1-038

**Claim:** The BRCA2 alteration c.5116_5119delAATA has a founder effect in North Africa.

**Citation:** `PMC7487731`, `abstract`, characters 546:1161

**Complete cited source span:**

> Overall, five BRCA germline mutations were identified (15.1%). The frequency of mutations among patients with family history of breast cancer was 16.7%. Three mutations were found in BRCA1 (9%) and two within the BRCA2 gene (6%). These are three frameshift mutations (c.798_799del, c.2125_2126insA, c.5116_5119delAATA), one missense (c.116G > A) and one nonsense mutation (c.289G > T). The mutation c.5116_5119delAATA has a founder effect in North Africa. Moreover, one variant of unknown significance was identified in BRCA2 (c.4090A > G). Most BRCA mutations carriers (80%) had no family history of breast cancer.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** While the span explicitly states that the mutation c.5116_5119delAATA has a founder effect in North Africa, it does not explicitly specify whether this specific alteration is located in the BRCA1 or BRCA2 gene.


---

## GCV1-039

**Claim:** ATM variants seem to increase breast cancer risk

**Citation:** `PMC3170966`, `abstract`, characters 617:1157

**Complete cited source span:**

> In childhood, total absence of ATM kinase activity was associated, almost exclusively, with development of lymphoid tumours. There was an overwhelming preponderance of tumours in patients <16 years without kinase activity compared with those with some residual activity, consistent with a substantial protective effect of residual ATM kinase activity against tumour development in childhood. In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part of the A-T phenotype.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses the A-T phenotype and total absence of ATM kinase activity leading to a 30-fold increased risk of breast cancer, but it does not explicitly state that ATM "variants" seem to increase breast cancer risk generically.


---

## GCV1-040

**Claim:** Mutations in CREBBP or EP300 are associated with increased recurrence after radiation in squamous cell carcinoma cohorts.

**Citation:** `PMC8566594`, `abstract`, characters 0:1090

**Complete cited source span:**

> Despite radiation forming the curative backbone of over 50% of malignancies, there are no genomically-driven radiosensitizers for clinical use. Herein we perform in vivo shRNA screening to identify targets generally associated with radiation response as well as those exhibiting a genomic dependency. This identifies the histone acetyltransferases CREBBP/EP300 as a target for radiosensitization in combination with radiation in cognate mutant tumors. Further in vitro and in vivo studies confirm this phenomenon to be due to repression of homologous recombination following DNA damage and reproducible using chemical inhibition of histone acetyltransferase (HAT), but not bromodomain function. Selected mutations in CREBBP lead to a hyperacetylated state that increases CBP and BRCA1 acetylation, representing a gain of function targeted by HAT inhibition. Additionally, mutations in CREBBP/EP300 are associated with recurrence following radiation in squamous cell carcinoma cohorts. These findings provide both a mechanism of resistance and the potential for genomically-driven treatment.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly and verbatim states that mutations in CREBBP/EP300 are associated with recurrence following radiation in squamous cell carcinoma cohorts.


---

## GCV1-041

**Claim:** Residual ATM kinase activity provides a protective effect against tumour development

**Citation:** `PMC12702395`, `body`, characters 23605:24042

**Complete cited source span:**

> Against our expectations based on the results from previous studies, CHEK2 c.1100delC associated ER-positive breast cancer patients had similar recurrent disease-free survival, distant disease-free survival, breast cancer-specific survival and overall survival as compared to non-carriers. However, when meta-analyzing our results with previous studies, CHEK2 c.1100delC was still associated with a worse breast cancer-specific survival.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses CHEK2 c.1100delC and breast cancer survival. It contains no information regarding ATM kinase activity or tumour development.


---

## GCV1-042

**Claim:** TP53 is altered in 2 of 9 (22%) small cell carcinoma of the uterine cervix

**Citation:** `PMC8847983`, `abstract`, characters 0:1948

**Complete cited source span:**

> Small cell carcinoma (SCC) of the uterine cervix is a rare and aggressive form of neuroendocrine carcinoma, which resembles small cell lung cancer (SCLC) in its histology and poor survival rate. Here, we sought to define the genetic underpinning of SCCs of the uterine cervix and compare their mutational profiles with those of human papillomavirus (HPV)‐positive head and neck squamous cell carcinomas, HPV‐positive cervical carcinomas, and SCLCs using publicly available data. Using a combination of whole‐exome and targeted massively parallel sequencing, we found that the nine uterine cervix SCCs, which were HPV18‐positive (n = 8) or HPV16‐positive (n = 1), harbored a low mutation burden, few copy number alterations, and other than TP53 in two cases no recurrently mutated genes. The majority of mutations were likely passenger missense mutations, and only few affected previously described cancer‐related genes. Using RNA‐sequencing, we identified putative viral integration sites on 18q12.3 and on 8p22 in two SCCs of the uterine cervix. The overall nonsilent mutation rate of uterine cervix SCCs was significantly lower than that of SCLCs, HPV‐driven cervical adeno‐ and squamous cell carcinomas, or HPV‐positive head and neck squamous cell carcinomas. Unlike SCLCs, which are reported to harbor almost universal TP53 and RB1 mutations and a dominant tobacco smoke‐related signature 4, uterine cervix SCCs rarely harbored mutations affecting these genes (2/9, 22% TP53; 0% RB1) and displayed a dominant aging (67%) or APOBEC mutational signature (17%), akin to HPV‐driven cancers, including cervical adeno‐ and squamous cell carcinomas and head and neck squamous cell carcinomas. Taken together, in contrast to SCLCs, which are characterized by highly recurrent TP53 and RB1 alterations, uterine cervix SCCs were positive for HPV leading to inactivation of the suppressors p53 and RB, suggesting that these SCCs are convergent phenotypes.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that 2 out of 9 (22%) of the uterine cervix SCCs harbored mutations affecting TP53.


---

## GCV1-043

**Claim:** Recent meta‑analysis found no worse outcome for CHEK2 c.1100delC carriers

**Citation:** `PMC4582980`, `abstract`, characters 0:1714

**Complete cited source span:**

> BRCA1-associated protein 1 (BAP1) is a deubiquitinating enzyme that is involved in the regulation of cell growth. Recently, many somatic and germline mutations of BAP1 have been reported in a broad spectrum of tumors. In this study, we identified a novel somatic non-synonymous BAP1 mutation, a phenylalanine-to-isoleucine substitution at codon 170 (F170I), in 1 of 49 patients with esophageal squamous cell carcinoma (ESCC). Multiplex ligation-dependent probe amplification (MLPA) of BAP1 gene in this ESCC tumor disclosed monoallelic deletion (LOH), suggesting BAP1 alterations on both alleles in this tumor. The deubiquitinase activity and the auto-deubiquitinase activity of F170I-mutant BAP1 were markedly suppressed compared with wild-type BAP1. In addition, wild-type BAP1 mostly localizes to the nucleus, whereas the F170I mutant preferentially localized in the cytoplasm. Microarray analysis revealed that expression of the F170I mutant drastically altered gene expression profiles compared with expressed wild-type BAP1. Gene-ontology analyses indicated that the F170I mutation altered the expression of genes involved in oncogenic pathways. We found that one candidate, TCEAL7, previously reported as a putative tumor suppressor gene, was significantly induced by wild-type BAP1 as compared to F170I mutant BAP1. Furthermore, we found that the level of BAP1 expression in the nucleus was reduced in 44% of ESCC examined by immunohistochemistry (IHC). Because the nuclear localization of BAP1 is important for its tumor suppressor function, BAP1 may be functionally inactivated in a substantial portion of ESCC. Taken together, BAP1 is likely to function as a tumor suppressor in at least a part of ESCC.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span is entirely about BAP1 mutations and esophageal squamous cell carcinoma (ESCC). It does not mention CHEK2 or any meta-analysis of outcomes.


---

## GCV1-044

**Claim:** Breast cancer is a commonly observed tumor in individuals with Cowden syndrome or PTEN hamartoma tumor syndrome.

**Citation:** `PMC11884457`, `body`, characters 0:878

**Complete cited source span:**

> Cowden syndrome (CS)/PTEN hamartoma tumor syndrome (PHTS) is a hereditary disorder characterized by autosomal dominant inheritance, caused by germline pathogenic variants in phosphatase and tensin homolog (PTEN) gene (1). Many CS/PHTS cases present with macrocephaly, distinctive facial skin lesions, and oral mucosal abnormalities (2), as well as developmental features such as autism spectrum disorders (3). These characteristics often lead to early diagnosis and referral to genetic clinics. However, cases without prominent external features may remain undiagnosed until adulthood. While the detailed mechanisms are not fully elucidated, PTEN loss-of-function leads to carcinogenesis. CS/PHTS patients are at increased risk for characteristic tumors such as breast, endometrial, and follicular thyroid cancer, often presenting at a younger age and potentially proving fatal.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that CS/PHTS patients are at an increased risk for characteristic tumors, specifically listing breast cancer.


---

## GCV1-045

**Claim:** Per‑standard‑deviation hazard ratios link PRS to increased ovarian cancer risk in BRCA1/BRCA2 carriers

**Citation:** `PMC5408990`, `body`, characters 9941:10117

**Complete cited source span:**

> Per-standard-deviation hazard ratios and 95% confidence intervals for the associations of polygenic risk scores with breast and ovarian cancer risk in BRCA1 and BRCA2 carriers*

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** This span is merely a title or caption for a table/figure indicating what data is presented. It does not explicitly state the result (that the hazard ratios link PRS to an *increased* risk).


---

## GCV1-046

**Claim:** ATM c.7570G>C is classified as a high‑risk allele for breast cancer

**Citation:** `PMC7384117`, `abstract`, characters 600:1458

**Complete cited source span:**

> A total of 16,501 BRCA1/2‐negative patients with breast cancer were analyzed. Deleterious PALB2 mutation carriers accounted for 0.97% (n = 160) in the breast cancer cohort and for 0.19% (n = 11) in the healthy control cohort. Forty‐one novel PALB2 germline mutations were identified. A high frequency of PALB2 c.751C>T was detected, and it accounted for 10.63% of the PALB2 germline mutations detected (17 of 160). PALB2 mutations were significantly associated with increased breast cancer risk (odds ratio [OR], 5.23; 95% confidence interval [CI], 2.84‐9.65; P < .0001), especially among women 30 years old or younger (OR, 10.09; 95% CI, 3.95‐25.79; P < .0001). Clinical characteristics, including a family history, bigger tumor size, triple‐negative breast cancer, positive lymph nodes, and bilateral breast cancer, were closely related to PALB2 mutations.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span exclusively discusses PALB2 mutations and breast cancer risk. It contains no information regarding the ATM c.7570G>C allele.


---

## GCV1-047

**Claim:** ATM variants seem to increase breast cancer risk

**Citation:** `PMC7786920`, `abstract`, characters 0:351

**Complete cited source span:**

> Ataxia telangiectasia-mutated (ATM) gene contributes to repair damaged DNA and to regulate cell cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants and the risk of breast cancer.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly and verbatim states that ATM variants seem to increase breast cancer risk.


---

## GCV1-048

**Claim:** PALB2 germline mutations markedly increase risk for women ≤30 years old

**Citation:** `PMC7384117`, `abstract`, characters 1459:1774

**Complete cited source span:**

> This study revealed a comprehensive spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer in China. PALB2 germline mutations confer a moderately increased risk for breast cancer but profoundly increase breast cancer risk for those 30 years old or younger in the Chinese population.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that PALB2 germline mutations profoundly increase breast cancer risk for those 30 years old or younger.


---

## GCV1-049

**Claim:** Recent large epidemiological and molecular studies provide conclusive evidence that ATM mutations causing ataxia‑telangiectasia are breast cancer susceptibility alleles

**Citation:** `PMC2386480`, `body`, characters 0:2149

**Complete cited source span:**

> The incidence of breast cancer in Chile is still increasing but the mortality rate in the last decade has remained constant. Early detection contributes to mortality reduction and genetic testing may identify high-risk individuals. Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have been identified as high penetrance alleles. However, these alleles explain only a small fraction of familial breast cancers [1,2]. We have previously screened for germ line mutations in BRCA1/2, 64 Chilean families with several cases of breast and/or ovarian cancer [3]. Only 15.6% of these presented mutations in one of these two genes. The most widely accepted model proposes that familial breast cancer susceptibility is a consequence of a small number of mutations in BRCA1/2 and a much larger variability in ethnic-specific genes of moderate and/or low penetrance [4]. The Ataxia-Telangiectasia Mutated gene (ATM) has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene. The ATM kinase has an essential role in maintaining genomic integrity. It is a key activator of the cellular responses to DNA double-strand breaks [5]. Individuals heterozygous for ATM mutations have been reported to have an increased risk for female breast cancer. A number of studies have searched for germ line ATM mutations in breast cancer cases and/or compared the frequency of common ATM variants among breast cancer cases to population controls, but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory [6,7]. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles [6,8]. There was no evidence that other classes of ATM variants confer a risk of breast cancer [8]. A common ATM variant IVS38-8T>C in cis with the 5557G>A ATM variant, has been suggested to be associated with bilateral breast cancer [9]. The 5557G>A variant has previously been reported in the homozygous state to associate with enhanced clinical radiosensitivity in breast cancer patients [10-12].

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span exactly matches the claim, explicitly stating that recent large epidemiological and molecular studies have provided conclusive evidence that ATM mutations causing ataxia-telangiectasia are breast cancer susceptibility alleles.


---

## GCV1-050

**Claim:** Higher PRS corresponds to higher absolute risk (6% vs 19% by age 80 for BRCA2 carriers across deciles)

**Citation:** `PMC137944`, `abstract`, characters 0:1098

**Complete cited source span:**

> The role of ataxia-telangiectasia mutated (ATM) heterozygosity in cancer is uncertain. In vitro studies of cells from ATM heterozygotes provide strong evidence of radiation sensitivity. Some, but not all, clinical studies suggest an increased risk of breast cancer among ATM gene carriers, and this risk may be greater among those exposed to radiation. This possible excess risk of breast cancer associated with ATM heterozygosity constitutes the basis for several genetic epidemiological studies designed to clarify the role that the ATM gene plays in the etiology of breast and other cancers. The primary focus of this international, multidisciplinary, National Cancer Institute-sponsored workshop was to discuss ongoing and planned epidemiologic studies aimed at understanding the complexities of the ATM gene and its role in carcinogenesis. The invited participants were from diverse disciplines including molecular and clinical genetics, radiation biology and physics, epidemiology, biostatistics, pathology, and medicine. In the present meeting report, the aims of each project are described.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses ATM heterozygosity and breast cancer risk. It does not contain any information regarding polygenic risk scores (PRS) or absolute risk percentages for BRCA2 carriers.


---

## GCV1-051

**Claim:** Recent large epidemiological and molecular studies provide conclusive evidence that ATM mutations causing ataxia‑telangiectasia are breast cancer susceptibility alleles

**Citation:** `PMC10092731`, `abstract`, characters 1:1307

**Complete cited source span:**

> ATM is generally described as a moderate‐risk breast cancer susceptibility gene. However, some of ATM variants might encounter higher risk. ATM c.7570G>C, p.Ala2524Pro, (rs769142993) is a pathogenic Finnish founder variant causative for recessively inherited ataxia‐telangiectasia. At cellular level, it has been reported to have a dominant‐negative effect. ATM c.7570G>C has recurrently been described in Finnish breast cancer families and unselected case cohorts collected from different parts of the country, but the rarity of the allele (MAF 0.0002772 in Finns) and lack of confirming segregation analyses have prevented any conclusive risk estimates. Here, we describe seven families from genetic counseling units with ATM c.7570G>C variant showing co‐segregation with breast cancer. Further analysis of the unselected breast cancer cohort from Northern Finland (n = 1822), a geographical region previously indicated to have enrichment of the variant, demonstrated that c.7570G>C significantly associates with breast cancer, and the risk is estimated as high (odds ratio [OR] = 8.5, 95% confidence interval [CI] = 1.04‐62.46, P = .018). Altogether, these results place ATM c.7570G>C variant among the high‐risk alleles for breast cancer, which should be taken into consideration in genetic counseling.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses the specific ATM c.7570G>C variant as a high-risk allele, but it does not make the broad statement that recent large epidemiological and molecular studies provide conclusive evidence about ATM mutations causing ataxia-telangiectasia in general being susceptibility alleles.


---

## GCV1-052

**Claim:** One study found similar survival outcomes, but meta‑analysis indicated worse breast‑cancer specific survival

**Citation:** `PMC12702395`, `body`, characters 23605:24042

**Complete cited source span:**

> Against our expectations based on the results from previous studies, CHEK2 c.1100delC associated ER-positive breast cancer patients had similar recurrent disease-free survival, distant disease-free survival, breast cancer-specific survival and overall survival as compared to non-carriers. However, when meta-analyzing our results with previous studies, CHEK2 c.1100delC was still associated with a worse breast cancer-specific survival.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly describes a finding of similar survival outcomes in one context, but states that meta-analyzing the results indicated a worse breast cancer-specific survival.


---

## GCV1-053

**Claim:** Absence of ATM kinase activity is linked to a markedly higher risk of lymphoid tumours in childhood

**Citation:** `PMC7788890`, `abstract`, characters 0:632

**Complete cited source span:**

> In addition to ovarian and breast cancers, loss-of-function mutations in BRCA1 and BRCA2 genes are also linked to an increased risk of pancreatic cancer, with ~ 4 to 7% of pancreatic cancer patients harboring germline BRCA mutations. Most BRCA alterations in pancreatic cancer are frame-shifting indels, stop-gain, and splice-site mutations, but single nucleotide substitutions are rare. Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline BRCA mutations and metastatic pancreatic cancer.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span discusses BRCA1 and BRCA2 mutations in relation to pancreatic cancer. It does not mention ATM kinase activity or lymphoid tumours in childhood.


---

## GCV1-054

**Claim:** The risk is especially high in women ≤30 years (OR 10.09)

**Citation:** `PMC7384117`, `abstract`, characters 600:1458

**Complete cited source span:**

> A total of 16,501 BRCA1/2‐negative patients with breast cancer were analyzed. Deleterious PALB2 mutation carriers accounted for 0.97% (n = 160) in the breast cancer cohort and for 0.19% (n = 11) in the healthy control cohort. Forty‐one novel PALB2 germline mutations were identified. A high frequency of PALB2 c.751C>T was detected, and it accounted for 10.63% of the PALB2 germline mutations detected (17 of 160). PALB2 mutations were significantly associated with increased breast cancer risk (odds ratio [OR], 5.23; 95% confidence interval [CI], 2.84‐9.65; P < .0001), especially among women 30 years old or younger (OR, 10.09; 95% CI, 3.95‐25.79; P < .0001). Clinical characteristics, including a family history, bigger tumor size, triple‐negative breast cancer, positive lymph nodes, and bilateral breast cancer, were closely related to PALB2 mutations.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly supports the claim, stating the risk is especially high among women 30 years old or younger and providing the exact odds ratio of 10.09.


---

## GCV1-055

**Claim:** No evidence that other classes of ATM variants confer breast cancer risk

**Citation:** `PMC10092731`, `abstract`, characters 1:1307

**Complete cited source span:**

> ATM is generally described as a moderate‐risk breast cancer susceptibility gene. However, some of ATM variants might encounter higher risk. ATM c.7570G>C, p.Ala2524Pro, (rs769142993) is a pathogenic Finnish founder variant causative for recessively inherited ataxia‐telangiectasia. At cellular level, it has been reported to have a dominant‐negative effect. ATM c.7570G>C has recurrently been described in Finnish breast cancer families and unselected case cohorts collected from different parts of the country, but the rarity of the allele (MAF 0.0002772 in Finns) and lack of confirming segregation analyses have prevented any conclusive risk estimates. Here, we describe seven families from genetic counseling units with ATM c.7570G>C variant showing co‐segregation with breast cancer. Further analysis of the unselected breast cancer cohort from Northern Finland (n = 1822), a geographical region previously indicated to have enrichment of the variant, demonstrated that c.7570G>C significantly associates with breast cancer, and the risk is estimated as high (odds ratio [OR] = 8.5, 95% confidence interval [CI] = 1.04‐62.46, P = .018). Altogether, these results place ATM c.7570G>C variant among the high‐risk alleles for breast cancer, which should be taken into consideration in genetic counseling.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `missing_information`

**Your rationale:** The span discusses a specific ATM variant (c.7570G>C) and estimates its risk, but it does not make any claim regarding a lack of evidence for other classes of ATM variants conferring breast cancer risk.


---

## GCV1-056

**Claim:** ATM c.7570G>C is classified as a high‑risk allele for breast cancer

**Citation:** `PMC10092731`, `abstract`, characters 1:1307

**Complete cited source span:**

> ATM is generally described as a moderate‐risk breast cancer susceptibility gene. However, some of ATM variants might encounter higher risk. ATM c.7570G>C, p.Ala2524Pro, (rs769142993) is a pathogenic Finnish founder variant causative for recessively inherited ataxia‐telangiectasia. At cellular level, it has been reported to have a dominant‐negative effect. ATM c.7570G>C has recurrently been described in Finnish breast cancer families and unselected case cohorts collected from different parts of the country, but the rarity of the allele (MAF 0.0002772 in Finns) and lack of confirming segregation analyses have prevented any conclusive risk estimates. Here, we describe seven families from genetic counseling units with ATM c.7570G>C variant showing co‐segregation with breast cancer. Further analysis of the unselected breast cancer cohort from Northern Finland (n = 1822), a geographical region previously indicated to have enrichment of the variant, demonstrated that c.7570G>C significantly associates with breast cancer, and the risk is estimated as high (odds ratio [OR] = 8.5, 95% confidence interval [CI] = 1.04‐62.46, P = .018). Altogether, these results place ATM c.7570G>C variant among the high‐risk alleles for breast cancer, which should be taken into consideration in genetic counseling.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that the results place the ATM c.7570G>C variant among the high-risk alleles for breast cancer.


---

## GCV1-057

**Claim:** Recent meta‑analysis found no worse outcome for CHEK2 c.1100delC carriers

**Citation:** `PMC12702395`, `body`, characters 28810:29984

**Complete cited source span:**

> Fourth, the definitions of outcomes are not always clearly described in the previous papers, especially regarding recurrent disease occurrences. Studies in our meta-analysis describing recurrent disease did not specify whether e.g. the occurrence of a second (contralateral) breast cancer diagnosis was defined as recurrent disease [7,8,12]. Increased risks of second (contralateral) breast cancer diagnosis have been described for CHEK2 c.1100delC breast cancer patients [[2], [3], [4], [5],11], and could therefore have been a reason for the increased risk of recurrent disease reported previously. Based on current literature, second (contralateral) breast cancer is often considered as a new primary breast cancer diagnosis [26,27], rather than a recurrent disease. However, these results have influenced the medical knowledge on prognosis, and more specifically on recurrent disease, for CHEK2 c.1100delC-associated breast cancer patients. Our current analysis is the first study on recurrent diseases and distant diseases specifically in ER-positive breast cancer patients, showing no worse outcome for CHEK2 c.1100delC breast cancer patients compared to non-carriers.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `contradiction`

**Your rationale:** The span actually contradicts the claim. The text describes their "current analysis" as showing no worse outcome, but notes earlier that other "Studies in our meta-analysis" were a reason for previously reported increased risks, and contextually, the meta-analysis found a worse outcome, not "no worse outcome."


---

## GCV1-058

**Claim:** TP53 mutations were independent predictors of worse survival in chondrosarcoma

**Citation:** `PMC13033615`, `abstract`, characters 732:1537

**Complete cited source span:**

> A total of 109 patients (53 females, 56 males; median age, 57 (16–89) years) were included. Tumor grades were G1/ACT (39%), G2 (41%), and G3/dedifferentiated (10%). Median follow‐up was 3.8 years with mortality of 17%. IDH mutations were detected in 59% (IDH1: 64%, IDH2: 36%), with dedifferentiated CS showing highest IDH mutation rate (91%), particularly IDH2. IDH2‐mutations were associated with significantly worse DSS compared to IDH–wild‐type or IDH1‐mutated tumors, independent of tumor grade. Specifically, IDH1‐R132C mutation correlated with significantly improved DSS compared to R132G, and IDH2‐R172S variant showed longest DSS and MFS, whereas IDH2‐R172T was linked to significant poor outcomes. In multivariable analysis, IDH2 and TP53 mutations were independent predictors of worse survival.

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly states that in multivariable analysis, TP53 mutations were independent predictors of worse survival (with CS contextually referring to chondrosarcoma).


---

## GCV1-059

**Claim:** No evidence that other classes of ATM variants confer breast cancer risk

**Citation:** `PMC2386480`, `body`, characters 0:2149

**Complete cited source span:**

> The incidence of breast cancer in Chile is still increasing but the mortality rate in the last decade has remained constant. Early detection contributes to mortality reduction and genetic testing may identify high-risk individuals. Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have been identified as high penetrance alleles. However, these alleles explain only a small fraction of familial breast cancers [1,2]. We have previously screened for germ line mutations in BRCA1/2, 64 Chilean families with several cases of breast and/or ovarian cancer [3]. Only 15.6% of these presented mutations in one of these two genes. The most widely accepted model proposes that familial breast cancer susceptibility is a consequence of a small number of mutations in BRCA1/2 and a much larger variability in ethnic-specific genes of moderate and/or low penetrance [4]. The Ataxia-Telangiectasia Mutated gene (ATM) has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene. The ATM kinase has an essential role in maintaining genomic integrity. It is a key activator of the cellular responses to DNA double-strand breaks [5]. Individuals heterozygous for ATM mutations have been reported to have an increased risk for female breast cancer. A number of studies have searched for germ line ATM mutations in breast cancer cases and/or compared the frequency of common ATM variants among breast cancer cases to population controls, but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory [6,7]. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles [6,8]. There was no evidence that other classes of ATM variants confer a risk of breast cancer [8]. A common ATM variant IVS38-8T>C in cis with the 5557G>A ATM variant, has been suggested to be associated with bilateral breast cancer [9]. The 5557G>A variant has previously been reported in the homozygous state to associate with enhanced clinical radiosensitivity in breast cancer patients [10-12].

**Your label:** `supported`

**Failure subtype, if applicable:**

**Your rationale:** The span explicitly matches the claim, stating there was no evidence that other classes of ATM variants confer a risk of breast cancer.


---

## GCV1-060

**Claim:** ~4–7% of pancreatic cancer patients harbor germline BRCA mutations

**Citation:** `PMC5325383`, `abstract`, characters 0:1797

**Complete cited source span:**

> Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1- and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval [95% CI], 1.85 - 7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% CI, 1.08 - 5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.

**Your label:** `unsupported`

**Failure subtype, if applicable:** `off_topic`

**Your rationale:** The span focuses entirely on proteomics of breast cancer models and TOP1/CDH3 expression. It contains no information regarding pancreatic cancer patients or germline BRCA mutations in that population.

---